Eledon Pharmaceuticals Inc - Asset Resilience Ratio
Eledon Pharmaceuticals Inc (ELDN) has an Asset Resilience Ratio of 46.52% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ELDN PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Eledon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ELDN net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Eledon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ELDN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.53 Million | 46.52% |
| Total Liquid Assets | $110.53 Million | 46.52% |
Asset Resilience Insights
- Very High Liquidity: Eledon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 46.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eledon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Eledon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Eledon Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Eledon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.52% | $110.53 Million | $237.60 Million | -20.91pp |
| 2024-12-31 | 67.43% | $119.63 Million | $177.41 Million | +30.50pp |
| 2023-12-31 | 36.93% | $46.49 Million | $125.89 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $92.79 Million | -- |
| 2016-12-31 | 14.03% | $4.17 Million | $29.76 Million | -44.72pp |
| 2015-12-31 | 58.75% | $39.93 Million | $67.97 Million | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more